Page 1168 - Hematology_ Basic Principles and Practice ( PDFDrive )

1019.e8 Part VII Hematologic Malignancies

311. Schwartzberg PL, Stall AM, Hardin JD, et al: Mice homozygous for the of acute lymphoblastic leukemia: A children’s oncology group study
ablm1 mutation show poor viability and depletion of selected B and T report. Biol Blood Marrow Transplant 13(2):218–227, 2007.
cell populations. Cell 65(7):1165–1175, 1991. 333. Kiehl MG, Kraut L, Schwerdtfeger R, et al: Outcome of allogeneic
312. Van Etten RA, Jackson P, Baltimore D: The mouse type IV c-abl gene hematopoietic stem-cell transplantation in adult patients with acute lym-
product is a nuclear protein, and activation of transforming ability is phoblastic leukemia: no difference in related compared with unrelated
associated with cytoplasmic localization. Cell 58(4):669–678, 1989. transplant in first complete remission. J Clin Oncol 22(14):2816–2825,
313. Lugo TG, Pendergast AM, Muller AJ, et al: Tyrosine kinase activity 2004.
and transformation potency of bcr-abl oncogene products. Science 334. Talano JM, Casper JT, Camitta BM, et al: Alternative donor bone
247(4946):1079–1082, 1990. marrow transplant for children with Philadelphia chromosome ALL.
314. Daley GQ, Baltimore D: Transformation of an interleukin 3-dependent Bone Marrow Transplant 37(2):135–141, 2006.
hematopoietic cell line by the chronic myelogenous leukemia-specific 335. von Bubnoff N, Peschel C, Duyster J: Resistance of Philadelphia-
P210bcr/abl protein. Proc Natl Acad Sci USA 85(23):9312–9316, 1988. chromosome positive leukemia towards the kinase inhibitor imatinib
315. Elefanty AG, Hariharan IK, Cory S: bcr-abl, the hallmark of chronic (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia
myeloid leukaemia in man, induces multiple haemopoietic neoplasms 17(5):829–838, 2003.
in mice. EMBO J 9(4):1069–1078, 1990. 336. Gorre ME, Sawyers CL: Molecular mechanisms of resistance to STI571
316. Gishizky ML, Johnson-White J, Witte ON: Efficient transplantation in chronic myeloid leukemia. Curr Opin Hematol 9(4):303–307, 2002.
of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in 337. Schultz KR, Bowman WP, Aledo A, et al: Improved early event-free
mice. Proc Natl Acad Sci USA 90(8):3755–3759, 1993. survival with imatinib in Philadelphia chromosome-positive acute
317. Kelliher M, Knott A, McLaughlin J, et al: Differences in oncogenic lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol
potency but not target cell specificity distinguish the two forms of the 27(31):5175–5181, 2009.
BCR/ABL oncogene. Mol Cell Biol 11(9):4710–4716, 1991. 338. Biondi A, Schrappe M, De Lorenzo P, et al: Imatinib after induction for
318. Cortez D, Reuther G, Pendergast AM: The Bcr-Abl tyrosine kinase treatment of children and adolescents with Philadelphia-chromosome-
activates mitogenic signaling pathways and stimulates G1-to-S phase positive acute lymphoblastic leukaemia (EsPhALL): a randomised,
transition in hematopoietic cells. Oncogene 15(19):2333–2342, 1997. open-label, intergroup study. Lancet Oncol 13(9):936–945, 2012.
319. Varticovski L, Daley GQ, Jackson P, et al: Activation of phosphati- 339. Bassan R, Rossi G, Pogliani EM, et al: Chemotherapy-phased imatinib
dylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell pulses improve long-term outcome of adult patients with Philadelphia
Biol 11(2):1107–1113, 1991. chromosome-positive acute lymphoblastic leukemia: Northern Italy
320. Reuther JY, Reuther GW, Cortez D, et al: A requirement for Leukemia Group protocol 09/00. J Clin Oncol 28(22):3644–3652,
NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 2010.
12(7):968–981, 1998. 340. Foa R, Vitale A, Vignetti M, et al: Dasatinib as first-line treatment for
321. Carlesso N, Frank DA, Griffin JD: Tyrosyl phosphorylation and DNA adult patients with Philadelphia chromosome-positive acute lympho-
binding activity of signal transducers and activators of transcription blastic leukemia. Blood 118(25):6521–6528, 2011.
(STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J 341. Ravandi F, O’Brien S, Thomas D, et al: First report of phase 2 study
Exp Med 183(3):811–820, 1996. of dasatinib with hyper-CVAD for the frontline treatment of patients
322. Raitano AB, Halpern JR, Hambuch TM, et al: The Bcr-Abl leukemia with Philadelphia chromosome-positive (Ph+) acute lymphoblastic
oncogene activates Jun kinase and requires Jun for transformation. Proc leukemia. Blood 116(12):2070–2077, 2010.
Natl Acad Sci USA 92(25):11746–11750, 1995. 342. Quintas-Cardama A, Kantarjian H, Cortes J: Imatinib and beyond–
323. Sawyers CL, McLaughlin J, Witte ON: Genetic requirement for Ras in exploring the full potential of targeted therapy for CML. Nat Rev Clin
the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl Oncol 6(9):535–543, 2009.
oncogene. J Exp Med 181(1):307–313, 1995. 343. Druker BJ: Circumventing resistance to kinase-inhibitor therapy. N
324. Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al: Engl J Med 354(24):2594–2596, 2006.
Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and 344. O’Hare T, Corbin AS, Druker BJ: Targeted CML therapy: controlling
is required for the growth of Philadelphia chromosome-positive cells. drug resistance, seeking cure. Curr Opin Genet Dev 16(1):92–99, 2006.
Blood 86(2):726–736, 1995. 345. Saito M, Gao J, Basso K, et al: A signaling pathway mediating down-
325. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al: Transformation regulation of BCL6 in germinal center B cells is blocked by BCL6 gene
of hematopoietic cells by BCR/ABL requires activation of a PI-3k/ alterations in B cell lymphoma. Cancer Cell 12(3):280–292, 2007.
Akt-dependent pathway. EMBO J 16(20):6151–6161, 1997. 346. Duy C, Hurtz C, Shojaee S, et al: BCL6 enables Ph+ acute lympho-
326. Skorski T: BCR/ABL regulates response to DNA damage: the role in blastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature
resistance to genotoxic treatment and in genomic instability. Oncogene 473(7347):384–388, 2011.
21(56):8591–8604, 2002. 347. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al: A subtype of
327. Ribeiro RC, Abromowitch M, Raimondi SC, et al: Clinical and bio- childhood acute lymphoblastic leukaemia with poor treatment outcome:
logic hallmarks of the Philadelphia chromosome in childhood acute a genome-wide classification study. Lancet Oncol 10(2):125–134, 2009.
lymphoblastic leukemia. Blood 70(4):948–953, 1987. 348. Mullighan CG, Su X, Zhang J, et al: Deletion of IKZF1 and prognosis
328. Crist W, Carroll A, Shuster J, et al: Philadelphia chromosome posi- in acute lymphoblastic leukemia. N Engl J Med 360(5):470–480, 2009.
tive childhood acute lymphoblastic leukemia: clinical and cytogenetic 349. Roberts KG, Morin RD, Zhang J, et al: Genetic alterations activating
characteristics and treatment outcome. A Pediatric Oncology Group kinase and cytokine receptor signaling in high-risk acute lymphoblastic
study. Blood 76(3):489–494, 1990. leukemia. Cancer Cell 22(2):153–166, 2012.
329. Fletcher JA, Lynch EA, Kimball VM, et al: Translocation (9;22) is 350. Loh ML, Zhang J, Harvey RC, et al: Tyrosine kinome sequencing of
associated with extremely poor prognosis in intensively treated children pediatric acute lymphoblastic leukemia: a report from the Children’s
with acute lymphoblastic leukemia. Blood 77(3):435–439, 1991. Oncology Group TARGET Project. Blood 121(3):485–488, 2013.
330. Arico M, Valsecchi MG, Camitta B, et al: Outcome of treatment in 351. Roberts KG, Li Y, Payne-Turner D, et al: Targetable kinase-activating
children with Philadelphia chromosome-positive acute lymphoblastic lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med
leukemia. N Engl J Med 342(14):998–1006, 2000. 371(11):1005–1015, 2014.
331. Balduzzi A, Valsecchi MG, Uderzo C, et al: Chemotherapy versus 352. Graux C, Cools J, Melotte C, et al: Fusion of NUP214 to ABL1 on
allogeneic transplantation for very-high-risk childhood acute lym- amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet
phoblastic leukaemia in first complete remission: comparison by 36(10):1084–1089, 2004.
genetic randomisation in an international prospective study. Lancet 353. Geng H, Hurtz C, Lenz KB, et al: Self-enforcing feedback activation
366(9486):635–642, 2005. between BCL6 and pre-B cell receptor signaling defines a distinct
332. Satwani P, Sather H, Ozkaynak F, et al: Allogeneic bone marrow trans- subtype of acute lymphoblastic leukemia. Cancer Cell 27(3):409–425,
plantation in first remission for children with ultra-high-risk features 2015.